Literature DB >> 97036

The immunogloblin nature of nephritic factor (NeF).

D M Scott, N Amos, J G Sissons, P J Lachmann, D K Peters.   

Abstract

NeF was shown to be antigenically and structurally similar to IgG by the following experiments: (1) NeF activity in serum was absorbed by and, under acid conditions, could be eluted from (a) anti-myeloma IgG antibody coupled to Sepharose and (b) protein A-Sepharose. (2) Purified NeF could bind to anit-myeloma IgG-Sepharose and could be eluted with acid, and this binding was blocked by myeloma IgG. (3) An antibody to beta2, microglobulin, showing strong cross-reactivity with normal IgG, bound NeF activity before, but not after, absorption of the antiserum with IgG. (4) Sepharose-coupled antibodies to NeF could bind activity which was recovered in the acid eluate. This binding capacity was lost after absorption of the antibody with normal and myeloma IgG. (5) Structural similarity was demonstrated by pepsin and papain digestion, which resulted in NeF activity eluting with F(ab')2 and Fab fragments from protein A-Sepharose and Sephadex G-150. (6) Autoradiography of PAGE-SDS of 125I-labelled NeF eluted from EA43bBb cells showed that NeF had a larger H chain than normal IgG, suggesting that NeF might be an abnormal IgG molecule.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 97036      PMCID: PMC1541306     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  ANTIGEN-ANTIBODY CROSSED ELECTROPHORESIS.

Authors:  C B LAURELL
Journal:  Anal Biochem       Date:  1965-02       Impact factor: 3.365

2.  The hydrolysis of rabbit y-globulin and antibodies with crystalline papain.

Authors:  R R PORTER
Journal:  Biochem J       Date:  1959-09       Impact factor: 3.857

3.  Biologically active water-insoluble protein polymers. I. Their use for isolation of antigens and antibodies.

Authors:  S Avrameas; T Ternynck
Journal:  J Biol Chem       Date:  1967-04-10       Impact factor: 5.157

4.  Role of C3b in the breakdown of C3 in hypocomplementaemic mesangiocapillary glomerulonephritis.

Authors:  D G Williams; P J Lachmann; J A Charlesworth; D K Peters
Journal:  Lancet       Date:  1973-03-03       Impact factor: 79.321

5.  The purification of specific antibody as F(ab')2 by the pepsin digestion of antigen-antibody precipitates, and its application to immunoglobulin and complement antigens.

Authors:  P J Lachmann
Journal:  Immunochemistry       Date:  1971-01

6.  Serum C'3 lytic system in patients with glomerulonephritis.

Authors:  R E Spitzer; E H Vallota; J Forristal; E Sudora; A Stitzel; N C Davis; C D West
Journal:  Science       Date:  1969-04-25       Impact factor: 47.728

7.  The cofactors required by C3 nephritic factor to generate a C3 convertase in vitro.

Authors:  N Amos; J G Sissons; J F Girard; P J Lachmann; D K Peters
Journal:  Clin Exp Immunol       Date:  1976-06       Impact factor: 4.330

8.  C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.

Authors:  M R Daha; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

9.  A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement.

Authors:  E H Vallota; O Götze; H L Spiegelberg; J Forristal; C D West; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307

10.  Characteristics of a non-complement-dependent C3-reactive complex formed form factors in nephritic and normal serum.

Authors:  E H Vallota; J Forristal; R E Spitzer; N C Davis; C D West
Journal:  J Exp Med       Date:  1970-06-01       Impact factor: 14.307

View more
  26 in total

1.  Complement activation profiles in disease.

Authors:  D L Brown
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

Review 2.  Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

Authors:  Marina Noris; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2018-06-09       Impact factor: 3.714

3.  Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.

Authors:  T E Mollnes; Y C Ng; D K Peters; T Lea; J Tschopp; M Harboe
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

4.  C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.

Authors:  Y C Ng; D K Peters
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

5.  Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor.

Authors:  M R Daha; L A Van Es
Journal:  Immunology       Date:  1981-05       Impact factor: 7.397

6.  Molecular analysis of C3 allotypes in patients with nephritic factor.

Authors:  J E Finn; P W Mathieson
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

Review 7.  The quest for an intrinsic C3 activating factor in human glomerular disease.

Authors:  J L Roberts; E J Lewis
Journal:  Surv Immunol Res       Date:  1982

8.  Stabilization of the classical pathway C3 convertase C42, by a factor F-42, isolated from serum of patients with systemic lupus erythematosus.

Authors:  M R Daha; H M Hazevoet; L A Vanes; A Cats
Journal:  Immunology       Date:  1980-07       Impact factor: 7.397

9.  Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus.

Authors:  D Adu; D G Williams
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

10.  Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN).

Authors:  H Ohi; T Yasugi
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.